Ollie.jpeg

Oliver Watson

Founder & Director

Ollie Watson received his PhD in Number Theory from the University of Pennsylvania, and has since worked in finance at D. E. Shaw and Tudor Capital, where he led a quantitative research team.  He is an expert on optimisation and statistical modelling in low signal-to-noise environments, and has taught courses on fitting predictive Bayesian models on noisy data.  In his spare time he is an avid skier.

Oliver Watson

Founder & Director

  • LinkedIn
Nick_image_edited_edited.jpg

Nick Firth

CEO & Director

Nicholas Firth studied for his PhD in Chemoinformatics at the Institute of Cancer Research, where he developed de novo design software. The piece of software Nick developed uses a fragment-based approach to explore chemistry space. Nick has a good understanding of many computational chemistry algorithms, feature engineering and machine learning for molecules.

Nick Firth

CEO & Director

  • LinkedIn
Capture d’écran 2021-07-07 à 15.52.58.png

Charles Jaskel

CBO

Charles has a finance background with a focus on investing, fundraising, and building technology focused businesses. This experience was gained during his tenure at Silver Lake Partners and more recently at QuantPort, a multi-billion dollar quantitative hedge-fund. His expertise covers investment and business development, from deal-structuring and portfolio construction through to recruiting and retaining talent.

Charles Jaskel

CBO

  • LinkedIn
13342864_1120808201303533_5042240648228842139_n_edited.jpg

Anna Hercot

COO

Anna graduated pre-med from Northwestern University as a neuroscience major.  Post pre-med, she studied coding and data science in Paris.  She previously helped businesses implement digital tools at a tech consulting company led by the French representative for digital initiatives at the European Commission and now leads operations at Evariste. 

Anna Hercot

COO

  • LinkedIn
IMG_5865_edited_edited.jpg

Alfie Brennan

Principal scientist

Alfie received a PhD in Medicinal Chemistry from Newcastle University, where he worked on fragment based drug discovery. He then moved to the Institute of Cancer Research, working on the lead optimisation of protein-protein interaction inhibitors. Alfie has worked on a variety of targets and has a keen interest in novel approaches to drug discovery and has worked on projects using both molecular glues and PROTACs to degrade proteins.

Alfie Brennan

Principal scientist

  • LinkedIn
Screenshot 2021-09-20 at 11.33.37.png

Noah Harisson

Chemoinformatician

Noah is a recent graduate of the University of Oxford where he received a MSc in Biochemistry. His research focussed on molecular dynamic simulations of mitochondrial supercomplex proteins and their interactions with lipid molecules. Noah’s other research interest centres around the conceptualisation and realisation of novel immunotherapies that are emerging as the fourth pillar of cancer therapy. Development of molecular docking procedures and integration into a virtual drug discovery pipeline therefore lies at the crossroad of his specialities.

Noah Harrison

Chemoinformatician

  • LinkedIn
Ovipond_edited.jpg

Oliver Vipond

Head of quant

Oliver studied for his Mathematics PhD at Worcester College, University of Oxford. He worked on developing new data analytic tools to describe the topology and geometry of data sets with interesting spatial structure, as well as studying the asymptotic topological properties of random simplicial complexes. Oliver is interested in developing statistically robust models and applying his expertise to the field of drug discovery.

Oliver Vipond

Head of quant

  • LinkedIn
WhatsApp Image 2022-01-31 at 22.15.35.jpeg

James Aaronson

Quantitative Analyst

James graduated from his Mathematics doctorate from Magdalen College, University of Oxford, where he studied combinatorics, particularly focusing on problems with an arithmetic flavour.

James Aaronson

Quantitative Analyst

  • LinkedIn

Team

Board of Directors

nmw123.jpg

Mike Waring

Scientific Director

Mike Waring holds the Chair of Medicinal Chemistry at Newcastle University, he is Head of Chemistry for the Cancer Research UK Newcastle Drug Discovery Unit and Director of the EPSRC Centre for Doctoral Training in Molecular Sciences for Medicine. Previously, he was Principal Scientist in Medicinal Chemistry at AstraZeneca, UK.  He is a highly experienced medicinal chemist with a track record of delivery of drug-discovery projects in oncology and cardiovascular indications, including fourteen candidate drugs for the treatment of cancer and diabetes, seven of which have thus far progressed to human trials and one has been approved by FDA (osimertinib, Tagrisso™) for the treatment of EGFR driven lung cancer.  He has a keen interest in small-molecule drug discovery and the development of novel hit generation and optimization approaches.  His work has been recognised by numerous international awards, including the inaugural Royal Society of Chemistry Biological and Medicinal Chemistry Lectureship (2014), the Malcolm Campbell medal (2017) and the American Chemical Society Heroes of Chemistry Prize (2018).
  • LinkedIn
20220201_104233 (1)_edited.jpg

Zoë Walters

Scientific Director

Dr Zoë Walters is a lecturer in translational epigenomics in the school of Cancer Sciences and is a Module Lead on the MSc Genomics within the Faculty of Medicine at the University of Southampton. Zoë is a highly experiences cancer biologist whose area of expertise lies primarily in target identification and validation in cancer and developmental disorders. Zoë has over 18 years’ experience in molecular genetics, developmental biology, and cancer biology. Taking a precision medicine approach, the work in her team focuses on target validation, single agent and combination testing of epigenetic therapies, 2D and 3D pre-clinical models, biomarker identification and validation, determining mechanism of action (targets and drugs), factors affecting therapy resistance/relapse and the role of cancer stem cells.
  • LinkedIn